Giuseppe Lamberti

Fixed-term researcher in Med Onc @unibo | Research interests: neuroendocrine tumors, SCLC, methods in clinical cancer research

[Lauren Averett Byers, MD @LaurenByersMD]

@ASCO #ASCO26
Highlight of the meeting was presenting the ABBV-706 (SEZ6 ADC) for R/R SCLC - with simultaneous publication in @NatureMedicine - these waterfalls plots!! Happy to be able to share the full data. @SclcSMASHERS @LUNGevity @UTMDAnderson

[Giuseppe Lamberti @GLambertiMD]

📯Just out: our Italian 🇮🇹 multicenter phase II trial of beva+atezo+PE in first-line ES-SCLC
🎯 1ary endpoint of OS met
📌Beva confirms PFS benefit in ES-SCLC
👀 on toxicity
🙏🏻 Thanks to all pts and caregivers
Thanks to all investigators
@Unibo
#SCLC #lungcancer

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study https://t.co/s6xmBxNfRL @GLambertiMD @CarloGenova5 @Unibo

[Giuseppe Lamberti @GLambertiMD]

💫 Just out our collaborative work suggesting that adding temozolomide to capecitabine (CAPTEM) 💊 may improve outcomes 📈 in patients with atypical carcinoids 🫁
🤩 Thanks to all the Authors (and friends) for their invaluable efforts
@SpringerNature

https://t.co/ppBmClQH8f

[OncoAlert @OncoAlert]

In metastatic non-small cell lung cancer treated w/ First-line pembrolizumab 🧪and cemiplimab

✅ PD-L1 expression ≥9⃣0⃣%, had significant3⃣year survival benefits 🆚 those with PD-L1 expression levels of 50-89%

Highlighting the potential for personalized treatment approaches in #NSCLC 🫁 based on PD-L1 levels.

Link: https://t.co/KrZA5xZ4Ud

@BiagioRicciutMD 🚨
@ArielleElkrief @JessicaJLinMD @GLambertiMD
@malini_gandhi @DiFedericoMD @pecci_federica1
@CMHidalgoFilho @cmpabon @lmsholl @CkapSaadettin @PetraRietschel @JustinGainor @DrMarkAwad

Pining our @OncoAlert 🚨 #LungCancer Faculty
Lung
@GlopesMd @NarjustFlorezMD @StephenVLiu @bmassutis @Tony_Calles @marinagarassino @peters_solange @UmbertoMalapel1 @g_mountzios @CharuAggarwalMD @christine_lovly @jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo @MartinReck2 @Latinamd @JulienMazieres @TerriConneran

#OncoAlertAF
@nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @dr_yakupergun @to_be_elizabeth

[Emre Yekedüz @yekeduz_emre]

🔥 A must-read review pertaining to "tumor mutational burden" , which is a predictor of response to PD(L)-1 inhibition 🎯

⭐️🔥✅Key points that should be kept in mind in terms of using TMB in clinical practice:🚨
🧬TMB is estimated using next-generation sequencing (NGS), whole genome (WGS), or whole exome sequencing (WES). Targeted panels of ≥0.8 Mb are used clinically, but accuracy drops below 0.5 Mb.
🧬High TMB correlates with better ICI outcomes in cancers like NSCLC and melanoma, but some low TMB cancers like RCC also respond well, indicating TMB alone doesn’t predict ICI efficacy.
🧬Trials show mixed results on TMB’s predictive value for ICI benefit. The KEYNOTE-158 study found a 30% response rate in high TMB tumors, leading to pembrolizumab approval for such cases.
🧬Despite approval, TMB’s role as a universal biomarker is not fully established, with questions remaining about its predictive power across different cancer types.

@GLambertiMD @myESMO @Annals_Oncology @OncoAlert @DanaFarber @BiagioRicciutMD

https://t.co/cLspz6AATn

[Nature Reviews Disease Primers @DiseasePrimers]

Our NEW Primer on Gastric neuroendocrine neoplasms is live today!
By @GLambertiMD, Panzuto, Pavel, O’Toole, Ambrosini, Falconi, Garcia-Carbonero, @RachelRiechelm2, Rindi & Campana.

Check it out here:
https://t.co/5TKccinPIV

[Dr. Karan Sood @QuantumOnc]

A pleasure meeting with 2 brilliant minds @aiom @DanaFarber group and such wonderful hosts. Grazie !
See you soon. #Aiom #Asco #Esmo #Oncology #ClinicalResearch #ResidentLife

[Giuseppe Lamberti @GLambertiMD]

I hope this finding will pave the way to new treatment options and outcome improvements for all patients. Thanks to the incredible team work with @BiagioRicciutMD and the terrific mentorship by @DrMarkAwad!

[Mark Awad @DrMarkAwad]

Now out in @JCO_ASCO, led by the outstanding @BiagioRicciutMD and @GLambertiMD, is our group's effort to elucidate mechanisms of resistance to PD-1 #immunotherapy in #lungcancer
https://t.co/4mh1jO5Mi5

[Dana-Farber News @DanaFarberNews]

In a new study published in @JCO_ASCO, @DrMarkAwad, @BiagioRicciutiMD, and @GLambertiMD @DanaFarber have uncovered mechanisms of resistance to immunotherapy in metastatic non-small-cell lung cancer.
Research Summary ▶️ https://t.co/epoCULbLla

[Giuseppe Lamberti @GLambertiMD]

@fmassari79 @vmollica7 @AIOMtweet Congrats, to your stellar team 💫 and their team leader! 🔝

[Talal El Zarif, MD @TalalZarif1]

Taking a moment to appreciate all the amazing people behind this study out today @JCO_ASCO that has been in the works for 2+ years. Hoping that it can guide oncologists caring for people living w/ #HIV and #cancer. https://t.co/zp5pLdQshs

[Raffaele Califano @caliraf]

Just published!

Great collaboration with Prof @LaurenByersMD and Prof Andrea Ardizzoni's Teams, led by Dr @lauramolinerj

Novel therapeutic strategies for recurrent SCLC.

@OncoAlert @UoM_DCS
@TheChristieSoO @BTOGORG
@mathew_carter1

https://t.co/ZUhmy3DpQi

[Laura Moliner @lauramolinerj]

What to do in SCLC after progression to 1st line? 💊

Our review focus in current and - hopefully 🤞- future options for these patients.

Many thanks to the rest of the team: @BZhangMD @GLambertiMD
@caliraf @LaurenByersMD and Prof Ardizzoni

https://t.co/ydIupOUZSz

#LCSM #SCLC

[Giuseppe Lamberti @GLambertiMD]

@GRecondoMD @JCOPO_ASCO @OncoAlert @DrMarkAwad Thank you, my friend! And thanks to Mark’s mentorship!

[JCO Precision Oncology @JCOPO_ASCO]

In this retrospective series, @GLambertiMD et al reported on intracranial activity of sotorasib in pts w/ #KRAS G12C mut #NSCLC ➡️ https://t.co/879diwFv5U @Oncoalert @DrMarkAwad #LCSM #JCOPO

[IASLC @IASLC]

The @IASLC's #TTLC23 Best Fellows Oral Abstract Session is going on now, with Drs. Lamberti, Cooper, Cheunkarndee and @LeiDeng3. #LCSM

[Giuseppe Lamberti @GLambertiMD]

@PARISIClau16 Pubmed?

[Mark Awad @DrMarkAwad]

Excited to be heading to Santa Monica for #TTLC with our research group! Very thankful to work with such kind and talented individuals every day @DanaFarber

[Giuseppe Lamberti @GLambertiMD]

@PARISIClau16 Grazie 😌